Preview

Rational Pharmacotherapy in Cardiology

Advanced search

ANTIARRHYTHMIC EFFICACY OF PROPAFENONE IN PATIENTS WITH PERSISTENT ATRIAL FIBRILLATION

https://doi.org/10.20996/1819-6446-2011-7-1-31-36

Full Text:

Abstract

Aim. To assess propafenone antiarrhythmic efficacy and optimal timing of the drug administration for relief of persistent atrial fibrillation (PAF). Material and methods. 24 patients (19 men, 5 women, aged 53,8±13,3) with PAF (duration is more than 7 days) were included in the study. PAF was confirmed clinically as well as by ECG and daily ECG monitoring. Indications for sinus rhythm recovery by propafenone were defined in according to the ACC/AHA/ESC recommendations (2006). 12-lead ECG was performed before the fist administration and 2, 4, 8, 12, 24 hours and some next days after propafenone therapy start. Echocardiography and thyroid hormone tests were also performed. Propafenone was administered additionally to standard treatment of the underlying disease and oral anticoagulants. The first dose of propafenone was 300 mg, after 4 hours patients received next dose of 300 mg if atrial fibrillation persisted and no side effects were observed, then doses of 300 mg were administered every 6-8 hours (but not more than 900-1200 mg per day) during 5 days. Maintenance propafenone dose of 450-600 mg daily was used in case of sinus rhythm recovery. Results. Sinus rhythm was restored in 41,6% of patients taking propafenone, and time of sinus rhythm recovery was 53,1±28,9 hours after therapy start. Propafenone antiarrhythmic efficacy in the loading dose (300 mg) was 4,2%. Propafenone efficacy during the first 24 hours (dose of 700±282,8 mg) was 12,5%. The maximum rate of sinus rhythm recovery was observed during the first 2-3 days of propafenone receiving (60% of all patients with rhythm recovery). Patients with unrecovered sinus rhythm had longer duration of PAF in comparison with this in effectively treated patients, 105,8±89,0 vs 39,7±38,9 days (p<0,05), respectively, as well as the more prominent basal pulse deficit, 24,6±15,0 vs 13,56±5,7 beats per minute (p<0,05), respectively. Cardiac and transient noncardiac side effects were registered in 8,6 and 4,3% of patients taking propafenone in dose of 900-1200 mg/day, respectively. Side effects did not require propafenone therapy cessation. Conclusion. Propafenone (900-1200 mg/day) antiarrhythmic efficacy in PAF was 41,6%. The probability of sinus rhythm recovery was maximal during the first 2-3 days. Ineffectively treated patients had longer duration of PAF last episode and more prominent basal pulse deficit in comparison with these in effectively treated patients. Transient side effects not requiring propafenone (900-1200 mg/day) withdrawal were observed in 12,6% of patients.

About the Authors

R. D. Kurbanov
Republican Cardiology Center
Uzbekistan


N. U. Zakirov
Republican Cardiology Center
Uzbekistan


Sh. K. Azizov
Republican Cardiology Center
Uzbekistan


References

1. Kushakovskiy M.S. Atrial fibrillation (causes, mechanisms, clinical forms, treatment, prevention). SPb.: IKF «Foliant»; 1999. Russian (Кушаковский М.С. Фибрилляция предсердий (причины, механизмы клинические формы, лечение, профилактика). СПб.: ИКФ «Фолиант»; 1999).

2. Kurbanov R.D., Zakirov N.U., Azizov Sh.K. Preventive efficacy of propafenone in patients with recurrent atrial fibrillation. Rossiyskiy kardiologicheskiy zhurnal 2009;6:40-44. Russian (Курбанов Р.Д., Закиров Н.У., Азизов Ш.К. Профилактическая эффективность пропафенона у больных с рецидивирующими формами фибрилляции предсердий. Российский кардиологический журнал 2009;6:40-44).

3. Kannel W.B., Wolf P.A., Benjamin E.J., Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82(8A):2N-9N.

4. ACC/AHH/ESC Guidlelines for the Management of Patients With Atrial Fibrillation: Executive Summary. Eur Heart J 2006:27(16):1979-2030.

5. Falk R.H., Decara J.M. Dofetilide: A new pure class III antiarrhythmic agent. Am Heart J 2000; 140(5):697-706.

6. Falk R.H., Pollak A.,Singh S.N. Friedrich T. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation of flatter. J Am Coll Cardiol 1997; 29(2): 385-390.

7. Kurbanov R.D., Zakirov N.U., Azizov Sh.K. Ways to improve the effectiveness of pharmacological cardioversion for recurrent atrial fibrillation. Kardiologiya Uzbekistana 2007; 2 (4): 12-15. Russian (Курбанов Р.Д., Закиров Н.У., Азизов Ш.К. Пути повышения эффективности фармакологической кардиоверсии при рецидивирующих формах фибрилляции предсердий. Кардиология Узбекистана 2007; 2 (4): 12-15).

8. Kurbanov R.D., Zakirov N.U., Azizov Sh.K. Effectiveness propanorm in providing emergency assistance in patients with recurrent atrial fibrillation. Vestnik ekstrennoy meditsiny 2008; 2: 57-61. Russian (Курбанов Р.Д., Закиров Н.У., Азизов Ш.К. Эффективность пропанорма в оказании экстренной помощи у больных при рецидивах фибрилляции предсердий. Вестник экстренной медицины 2008; 2: 57-61).

9. Fomina I.G., Tarzimanova A.I., Vetluzhskiy A.V., Abramova A.A. Propafenone in restoring and maintaining sinus rhythm in patients with persistent atrial fibrillation. " PROMETEY" -an open multicenter study in Russia. Rational pharmacotherapy in cardiology 2006; 1:37-

10. Russian (Фомина И.Г., Тарзиманова А.И., Ветлужский А.В., Абрамова А.А. Пропафенон при восстановлении и сохранении синусового ритма у больных с персистирующей формой фибрилляции предсердий. «ПРОМЕТЕЙ» — открытое мультицентровое исследование в РФ. Рациональная Фармакотерапия в Кардиологии 2006; 1:37-40).

11. Kochiadakis G.E., Igoumenidis N.E., Parthenakis F.I., Chlouverakis G.I., Vardas P.E. Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol 1999;33(4):966-71.

12. Henry W.L., DeMaria A., Gramiak R. et al. Report of the American Society of Echocardiography Committee on Nomenclature and Standards in Two-dimensional Echocardiography. Circulation 1980;62(2):212-7.

13. Devereux R.B., de Simone G., Ganau A. et al. Left ventricular hypertrophy and hypertension. Clin Exp Hypertens 1993;15(6):1025-32.

14. Chuchalin A.G., Vyalkov A.I., Belousov Yu.B., Yasnetsov V.V., editors. Federal guidelines on the use of drugs (formulary system). Issue VIII. M.: EKhO; 2007. S. 156-158. Russian (Чучалин А.Г., Вялков А.И., Белоусов Ю.Б., Яснецов В.В., редакторы. Федеральное руководство по использованию лекарственных средств (формулярная система). Выпуск VIII. М.: ЭХО; 2007. С. 156-158).

15. Wijffels M.C., Kirchhoff C.J., Dorland R., Allesie M.A. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation 1995;92(7): 1954-68.

16. Preobrazhenskiy D.V. Atrial fibrillation in elderly patients. Klinicheskaya gerontologiya 2008; 11: 42-49. Russian (Преображенский Д.В. Мерцание предсердий у больных пожилого возраста. Клиническая геронтология 2008; 11: 42-49).

17. Tatarsky B.A. Paroxysmal atrial fibrillation: treatment choice. Kardiovaskulyarnaya terapiya i profilaktika 2007; 6 (3):82 - 89. Russian (Татарский Б.А. Пароксизмальные формы фибрилляции предсердий: выбор купирующей терапии. Кардиоваскулярная терапия и профилактика 2007; 6 (3):82 – 89).

18. Deedwania P.C., Singh B.N., Ellenbogen K. et al. Spontaneous Сonversion and Maintenance of Sinus Rhythm by Amiodarone in Pathients With Heart Failure and Atrial Fibrillation. Circulation 1998; 98(23): 2574-2579.

19. Boytsov S.A. Atrial Fibrillation. SPb.: ELBI-SPb; 2001. Russian (Бойцов С.А. Мерцатель-ная аритмия. СПб.: ЭЛБИ-СПб; 2001).


For citation:


Kurbanov R.D., Zakirov N.U., Azizov S.K. ANTIARRHYTHMIC EFFICACY OF PROPAFENONE IN PATIENTS WITH PERSISTENT ATRIAL FIBRILLATION. Rational Pharmacotherapy in Cardiology. 2011;7(1):31-36. (In Russ.) https://doi.org/10.20996/1819-6446-2011-7-1-31-36

Views: 660


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)